非感染性眼部炎症治疗进展

Current strategies and new avenues in the management of non-infectious ocular inflammation

非感染性眼部炎症是世界范围内主要的致盲性眼病之一,常常提示系统性自身免疫性疾病的发生。目前的治疗方法主要是使用皮质类固醇激素和免疫抑制剂。然而,常规治疗并非对所有患者均有效,因此还需给予生物反应调节剂治疗。生物反应调节剂从本质上更为有效,但通常不是首选药物。尽管如此,由于眼部独特的生理解剖学特征和自身免疫性疾病的整体复杂性,非感染性眼部炎症的治疗后缓解率无明显改善。新出现的生物药物制剂和纳米技术在药物传输系统中的应用,有望大大改善非感染性眼部炎症的临床疗效。

Non-infectious ocular inflammation is one of the major causes of blindness worldwide and often heralds the onset of systemic autoimmune pathologies.Current therapeutic approaches are based on the use corticosteroid and immunosuppressant.However,not all patients respond well to conventional therapy,consequently they are offered biological response modifiers.They are fundamentally more effective,but it is not typically recommended at first.Nevertheless,the remission rate has not change significantly,primarily due to the unique physio-anatomical features of the eye and overall complexity of autoimmune diseases.The emergence of new biopharmaceutical formulation model and the use of nanotechnology in drug delivery hope to greatly improve clinical outcome.